AI-generated analysis. Always verify with the original filing.
BioXcel Therapeutics reported financial results for Q4 and full-year 2025, including net revenue of $256,000 for Q4 and $642,000 for the full year, and a net loss of $12.5 million for Q4 and $69.9 million for the full year. The company also announced the submission of an sNDA in January seeking label expansion for IGALMI in the at-home setting, with potential approval as early as year-end 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amende
Financial Statements and Exhibits. (d) Exhibits. Ex. No. Description 99.1 Press release 104 Cover Page Interactive Data File - the cover page XBRL tags are embe
| Metric | Value | Basis |
|---|---|---|
| Net revenue from IGALMI | $256.0K | |
| Cost of Goods Sold | $32.0K | |
| Research and Development expenses | $6.7M | |
| Selling, General and Administrative expenses | $3.8M | |
| Operating loss | $10.3M | |
| Net loss | $12.5M |
Mark Pavao
to lead the development and execution of the launch plans for IGALMI in the at-home setting